Procept BioRobotics Corp (NASDAQ: PRCT)’s stock price has dropped by -2.71 in relation to previous closing price of 57.59. Nevertheless, the company has seen a loss of -7.51% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-11 that PROCEPT BioRobotics shows strong revenue growth and expanding market presence but struggles with profitability and rising operational costs. The company’s HYDROS robotic system and consumables business are driving revenue, with significant expansion in the U.S. and promising international growth. The FDA’s clearance for Aquablation therapy in prostate cancer patients presents a long-term opportunity, though profitability remains a distant goal.
Is It Worth Investing in Procept BioRobotics Corp (NASDAQ: PRCT) Right Now?
PRCT has 36-month beta value of 1.09. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for PRCT is 51.84M, and currently, short sellers hold a 9.80% ratio of that float. The average trading volume of PRCT on March 14, 2025 was 883.15K shares.
PRCT’s Market Performance
PRCT’s stock has seen a -7.51% decrease for the week, with a -15.11% drop in the past month and a -39.44% fall in the past quarter. The volatility ratio for the week is 6.50%, and the volatility levels for the past 30 days are at 6.34% for Procept BioRobotics Corp. The simple moving average for the past 20 days is -11.32% for PRCT’s stock, with a -24.94% simple moving average for the past 200 days.
Analysts’ Opinion of PRCT
Many brokerage firms have already submitted their reports for PRCT stocks, with Morgan Stanley repeating the rating for PRCT by listing it as a “Overweight.” The predicted price for PRCT in the upcoming period, according to Morgan Stanley is $105 based on the research report published on December 02, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see PRCT reach a price target of $95. The rating they have provided for PRCT stocks is “Hold” according to the report published on November 14th, 2024.
Piper Sandler gave a rating of “Overweight” to PRCT, setting the target price at $42 in the report published on August 11th of the previous year.
PRCT Trading at -20.97% from the 50-Day Moving Average
After a stumble in the market that brought PRCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.03% of loss for the given period.
Volatility was left at 6.34%, however, over the last 30 days, the volatility rate increased by 6.50%, as shares sank -15.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.68% lower at present.
During the last 5 trading sessions, PRCT fell by -7.51%, which changed the moving average for the period of 200-days by -16.03% in comparison to the 20-day moving average, which settled at $63.18. In addition, Procept BioRobotics Corp saw -30.41% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PRCT starting from Nouri Alaleh, who sale 3,641 shares at the price of $61.31 back on Mar 06 ’25. After this action, Nouri Alaleh now owns 61,789 shares of Procept BioRobotics Corp, valued at $223,230 using the latest closing price.
Shiblaq Hisham, the EVP, Chief Comm. Officer of Procept BioRobotics Corp, sale 3,588 shares at $61.31 during a trade that took place back on Mar 06 ’25, which means that Shiblaq Hisham is holding 63,380 shares at $219,980 based on the most recent closing price.
Stock Fundamentals for PRCT
Current profitability levels for the company are sitting at:
- -0.43 for the present operating margin
- 0.61 for the gross margin
The net margin for Procept BioRobotics Corp stands at -0.41. The total capital return value is set at -0.2. Equity return is now at value -26.77, with -19.48 for asset returns.
Based on Procept BioRobotics Corp (PRCT), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at -1.24. The debt to equity ratio resting at 0.2. The interest coverage ratio of the stock is -23.09.
Currently, EBITDA for the company is -82.0 million with net debt to EBITDA at 3.09. When we switch over and look at the enterprise to sales, we see a ratio of 12.55. The receivables turnover for the company is 2.69for trailing twelve months and the total asset turnover is 0.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.07.
Conclusion
To put it simply, Procept BioRobotics Corp (PRCT) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
